Company / R&D Expense
CytomX Therapeutics, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$68.7M
FY2025
5-year range
$68.7M / $114.2M
FY2021-FY2025
Trend
-17.6%
vs FY2024
Sector context
#167 of 210
Health Care
What the data says
CytomX Therapeutics, Inc.'s r&d expense of $69M is lower than 80% of companies in the Health Care sector (FY2025). R&D Expense has fluctuated over the past 10 years, ranging from $55M in FY2016 to $132M in FY2019.
Based on SEC 10-K filings.
$69M in FY2025 with a 5-year CAGR of -9.5%.
Declined from $78M to $69M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -14.9%
- 5-Year CAGR
- -9.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 210This company $68.7M Sector average $644.1M
▼
-89.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -9.5%, indicating a declining trend.
- In FY2025, r&d expense decreased 17.6% year-over-year.
- Ranks #167 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $68.7M | -17.6% |
| FY2024 | $83.4M | +7.3% |
| FY2023 | $77.7M | -30.4% |
| FY2022 | $111.6M | -2.2% |
| FY2021 | $114.2M | +1.1% |
| FY2020 | $112.9M | -14.2% |
| FY2019 | $131.6M | +26.7% |
| FY2018 | $103.9M | +12.6% |
| FY2017 | $92.3M | +68.5% |
| FY2016 | $54.8M | +402.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026